Relay Therapeutics, Inc.

The momentum for this stock is not very good. Relay Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Relay Therapeutics, Inc..

News

Relay Therapeutics (NASDAQ:RLAY) Lowered to "Market Perform" at Oppenheimer

Zolmax Relay Therapeutics (NASDAQ:RLAY - Get Free Report) was downgraded by Oppenheimer from an "outperform" rating to a "market perform" rating in a note issued to investors on Tuesday, MarketBeat Ratings...\n more…

JPMorgan Chase & Co. Lowers Relay Therapeutics (NASDAQ:RLAY) Price Target to $21.00

Zolmax Relay Therapeutics (NASDAQ:RLAY - Get Free Report) had its target price cut by research analysts at JPMorgan Chase Co. from $23.00 to $21.00 in a report issued on Tuesday, Benzinga reports...\n more…

Relay Therapeutics (NASDAQ:RLAY) PT Raised to $24.00 at Bank of America

Ticker Report Relay Therapeutics (NASDAQ:RLAY - Get Free Report) had its target price lifted by research analysts at Bank of America from $20.00 to $24.00 in a report issued on Tuesday, Benzinga reports. The firm...\n more…

Jefferies Financial Group Upgrades Relay Therapeutics (NASDAQ:RLAY) to "Buy"

Ticker Report Relay Therapeutics (NASDAQ:RLAY - Get Free Report) was upgraded by equities researchers at Jefferies Financial Group from a "hold" rating to a "buy" rating in a research note issued on Tuesday...\n more…

Relay Therapeutics (NASDAQ:RLAY) Upgraded by Jefferies Financial Group to Buy

Zolmax Relay Therapeutics (NASDAQ:RLAY - Get Free Report) was upgraded by equities researchers at Jefferies Financial Group from a "hold" rating to a "buy" rating in a research report issued to clients and...\n more…

Barclays Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00

Zolmax Relay Therapeutics (NASDAQ:RLAY - Get Free Report) had its price objective boosted by research analysts at Barclays from $14.00 to $17.00 in a research note issued on Tuesday, Benzinga reports. The...\n more…